4.93
0.07 (1.44%)
| 前收盘价格 | 4.86 |
| 收盘价格 | 4.83 |
| 成交量 | 1,201,139 |
| 平均成交量 (3个月) | 1,827,214 |
| 市值 | 688,541,888 |
| 价格/销量 (P/S) | 64.26 |
| 股市价格/股市净资产 (P/B) | 4.21 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2026 |
| 营业利益率 (TTM) | -1,222.27% |
| 稀释每股收益 (EPS TTM) | -1.59 |
| 季度收入增长率 (YOY) | -39.30% |
| 总债务/股东权益 (D/E MRQ) | 1.72% |
| 流动比率 (MRQ) | 5.06 |
| 营业现金流 (OCF TTM) | -12.32 M |
| 杠杆自由现金流 (LFCF TTM) | -52.41 M |
| 资产报酬率 (ROA TTM) | -18.20% |
| 股东权益报酬率 (ROE TTM) | -91.03% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Aclaris Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.13 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.69% |
| 机构持股比例 | 88.24% |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| GOWEN MAXINE | - | - | 0 | 0 |
| HUMPHRIES WILLIAM D. | - | - | 0 | 0 |
| MEHRA ANAND | - | - | 0 | 0 |
| MILANO VINCENT | - | - | 0 | 0 |
| MOLINEAUX CHRISTOPHER P. | - | - | 0 | 0 |
| SCHIFF ANDREW N | - | - | 0 | 0 |
| 累积净数量 | 0 | |||
| 累积净值 ($) | 0 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| GOWEN MAXINE | 董事 | 05 Jun 2026 | 执行期权 | 11,580 | - | - |
| MEHRA ANAND | 董事 | 05 Jun 2026 | 执行期权 | 11,580 | - | - |
| HUMPHRIES WILLIAM D. | 董事 | 05 Jun 2026 | 执行期权 | 11,580 | - | - |
| SCHIFF ANDREW N | 董事 | 05 Jun 2026 | 执行期权 | 11,580 | - | - |
| MILANO VINCENT | 董事 | 05 Jun 2026 | 执行期权 | 11,580 | - | - |
| MOLINEAUX CHRISTOPHER P. | 董事 | 05 Jun 2026 | 执行期权 | 11,580 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合